Regenxbio (RGNX) Stock Price, Quote, News & History | Benzinga

Regenxbio Inc (RGNX) Stock Price, Quote, News & History

RGNXNASDAQ

Trade with Public

Trade with Public

$10.91

0.262.44%

At close: Aug 12, 5:00 PM EST

$10.86

-0.0499-0.46%

After Hours: 6:38 PM EST

Earnings: Q2 2026 Earnings were released on Thu Aug 6th, before the market open

Conference Call: The most recent conference call started at 8:00 AM, 7 days ago

Click to view the webcast

OverviewNews Earnings Forecast Events Price Targets Financials Sentiment Ownership Compare Options Stock Report

Key Statistics

Open

$10.77

Close

$10.91

Volume / Avg.

877.34K / 2.22M

Day Range

$10.68 - $11.21

52 Wk Range

5.46 - 16.19

Market Cap

$716.91M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

55

Short Interest

11.54%

Days to Cover

3.79

Recent REGENXBIO Inc. News

This NetApp Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Monday

Wall Street analysts upgraded PTGX, LECO, and JHX. See analyst ratings and price targets for these stocks.

Avi Kapoor

This Tower Semiconductor Analyst Begins Coverage On A Bullish Note; Here Are Top 2 Initiations For Friday

Wall Street analysts changed outlook on top names. For rating changes, check our analyst ratings page. See analysts' views on ADIG, TSEM and more

Avi Kapoor

This HubSpot Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday

Top Wall Street analysts changed outlook on top names. For all changes & stock ratings, see analyst ratings page. Some stocks downgraded & price targets lowered.

Avi Kapoor

These 7 Small Caps Are on Fire as the Second Half Begins: Here’s Why

Seven small-cap stocks have surged as much as 123% in early July on buyouts, FDA developments, refinancing deals and short squeezes.

Piero Cingari

Clinical Trial Results Show Extended Benefits for REGENXBIO Retinal Treatments

REGENXBIO announced positive long-term sura-vec trial data for wet AMD and diabetic retinopathy, alongside a $100 million offering.

Vandana Singh

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-246.67M

Investing Cash Flow (TTM)

216.34M

Financing Cash Flow (TTM)

-12.74M

Free Cash Flow (TTM)

-249.67M

Capital Expenditure (TTM)

-2.99M

Net Change in Cash (TTM)

-43.07M

Analyst Trends and Forecast

2

Mar

2

May

4

Jun

1

1

Aug

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

3.9

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$684.23M

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

3.27

PB Ratio (TTM)

10.04

Earnings Yield % (TTM)

-34.62%

Earnings Yield % (FWD)

-26.61%

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

$1.09

Company Debt

Total Debt

-

LT Debt

-

LT Debt Issuance (TTM)

-$33.00K

LT Debt Repayment (TTM)

-

Total Cash

$36.49M

Debt to Equity

0.96

Issuance of Debt (TTM)

-$33.00K

Repayment of Debt (TTM)

-

Key Statistics

Open

$10.77

Close

$10.91

Volume / Avg.

877.34K / 2.22M

Day Range

$10.68 - $11.21

52 Wk Range

5.46 - 16.19

Market Cap

$716.91M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

55

Short Interest

11.54%

Days to Cover

3.79

About

Sector

Health Care

Industry

Biotechnology

Regenxbio Inc is a clinical-stage biotechnology company focused on the development of gene therapy treatments. Its product candidates are designed to deliver genes to cells to address genetic defects or enable the production of therapeutic proteins. ...

Show More

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

Q

How do I buy Regenxbio (RGNX) stock?

A

You can purchase shares of Regenxbio (NASDAQ:RGNX) through any online brokerage.

View our list of the best stock brokerages

Q

Who are Regenxbio (RGNX) competitors?

A

Other companies in Regenxbio’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).

Q

What is the forecast, or price target, for Regenxbio (RGNX) stock?

A

Regenxbio has a consensus price target of $25.33.

Q

What is the current price for Regenxbio (RGNX)?

A

The stock price for Regenxbio (NASDAQ: RGNX) is $10.8601 last updated August 12, 2026 at 6:38 PM EDT.

Q

Does Regenxbio (RGNX) pay a dividend?

A

There are no upcoming dividends for Regenxbio.

Q

When is Regenxbio (NASDAQ:RGNX) reporting earnings?

A

Regenxbio does not have any upcoming earnings scheduled.

Q

Is Regenxbio (RGNX) going to split?

A

There is no upcoming split for Regenxbio.

Q

What sector and industry does Regenxbio (RGNX) operate in?

A

Regenxbio is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.